Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 15, 2010 (Vol. 30, No. 4)

Trends in Monoclonal Antibody Production

With Capacity Issues Resolved, Firms Direct Attention to Quality, Timelines, and Cost

  • In the decade since severe capacity constraints limited monoclonal antibody (mAb) production, the industry has adjusted, so that today, overcapacity is the issue, along with developing techniques to ensure product quality, reduce development timelines, and decrease costs. Many of these issues will be explored next month at IBC’s conference ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.